Vladimir Anisimov

Principal Data Scientist, Data Science, Center for Design & Analysis - Amgen

Dr Anisimov has an experience in pharma industry for more than 20 years. Currently Principal Data Scientist, Data Science, Center for Design & Analysis, Amgen, based in London, UK, and is leading the development of the innovative statistical technologies for modeling/forecasting and optimal designing some operational characteristics in clinical trials. Prior to this, he worked for GlaxoSmithKline and Quintiles (IQVIA).

Had also been granted the status of Honorary Professor in the School of Mathematics and Statistics, University of Glasgow, UK (2011-2018). Internationally recognized expert in statistical modelling of clinical trials.
Vladimir started his career in academia and prior to switching to pharma industry worked as university professor. Founded the Applied Statistics Department at Kiev National University, Ukraine and served for more than 20 years as Professor & Head of this Department.


Received PhD, ScD degrees and diploma of Professor in Applied Statistics, published more than 200 papers (~ 50 in clinical trials modelling) and several books, supervised 24 PhD theses. Led a numerous number of various projects and some EU and UK grants.

Vladimir Anisimov


  • Wednesday - September 21, 2022 - 11:55

    Advanced analytic technologies for predictive modelling and optimizing patient recruitment in clinical trials

    • Analytic modelling and forecasting patient recruitment
    • Optimal operational design, sites/countries selection given costs & time constraints
    • Data-driven re-projection and optimal adjustment of recruitment to increase probability to meet target
    • Centralized statistical monitoring and detecting unusual data patterns
    • Predicting some operational characteristics

  • Wednesday - September 21, 2022 - 14:15

    Panel discussion: Effective patient recruitment and retention in clinical trials to boost trial success

    • What will persuade and impact the patient?
    • Is there anything pharma can provide for a trial member that will increase the value of participation?
    • The aim of patient-driven clinical trials is to diminish the burden of participation by making the participant journey as convenient and pleasant as possible
    • Utilize fitting procedures and techniques to limit dropouts without, in any capacity, constraining a patient to remain in the study
    • Utilize wider use of the innovative statistical and Machine Learning techniques to provide more accurate data-driven forecasting and centralized monitoring of patient recruitment


Stay Informed

Subscribe today to receive news on latest updates,
offers and upcoming conferences via email

For general conference and registration enquires please contact the below email id or fill out the form

Enquire now